Vanguard Group Inc Erasca, Inc. Put Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
149Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$48.4 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$43.3 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$38 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$32 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$30.9 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $260M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...